Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We are reverting to a Neutral recommendation on SurModics Inc. (SRDX - Analyst Report) from Outperform as we believe that the stock is fairly valued at current levels. Our target price is $19.00. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

In November 2012, SurModics came out with decent numbers for the fourth quarter of fiscal 2012 (ended September 30, 2012). The company’s fourth quarter fiscal 2012 adjusted earnings of 19 cents per share beat the Zacks Consensus Estimate by 2 cents. Adjusted revenues climbed 12.3% to $13.8 million in the final quarter of fiscal 2012. Strong sales of vitro diagnostics offerings and hydrophilic coatings boosted revenues.

We note that SurModics has taken a number of steps to improve efficiency following its disappointing performance in fiscal 2010. The company trimmed its work-force and made certain changes to its organizational structure to improve efficiencies.

Moreover, following the disappointing performance in fiscal 2010, SurModics revamped its board of directors and also brought about a change at its helm, with the appointment of a new CEO, Gary R. Maharaj. We note that Maharaj is the former President and CEO of Arizant Inc., which was sold to 3M Company (MMM - Analyst Report) in October 2010. We are positive on the sale of SurModics’ Pharmaceuticals unit in 2011 as this has allowed the company to focus on its core businesses.

However, since royalties are a major source of revenues at SurModics, any royalty related setback will affect the top line. For example, Johnson & Johnson’s (JNJ - Analyst Report) decision to stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents, from which SurModics earned royalties, affected SurModics’ top line. Setbacks of a similar nature will negatively impact SurModics’ stock price.

While encouraged by the steps taken by the company to revive itself, we see limited upside potential for the stock from current levels.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%